This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM’s proprietary technology and is bioequivalent to the Innovator’s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops,
manufactures, and supplies differentiated generic products in oral solid dosage forms across key
therapeutic segments.
The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023.
The scrip rose 0.27% currently trade at to Rs 85 on the BSE.